Literature DB >> 10938591

Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study.

M Ogawa1, M Kawamoto, N Yamanaka.   

Abstract

Unlike other tissues, bone marrow (BM) seldom displays fibrosis after injury, suggesting a possible suppressive mechanism against secondary myelofibrosis in BM tissues. We investigated if fibrosis-related factors, such as matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP), were expressed in BM tissues in vivo. We attempted immunohistochemical studies on specimens of 16 BM aspiration materials with normal hematological findings and 21 BM tissues from autopsy cases who had succumbed to acute heart failure or cerebrovascular diseases without any BM injuries. Identification of immunohistochemically reactive MMP-2, MMP-9 and TIMP-2 in BM tissue samples revealed for the first time that MMP-2 was localized in the myeloid cells, erythroblasts and megakaryocytes, MMP-9 in the myeloid cells and megakaryocytes. In addition, expression of TIMP-2 in the megakaryocytes as well as in the histiocytes within the stroma was verified. In the non-pathological condition, MMP/TIMP expressions were not encountered in BM stromal cells, such as fibroblasts, vascular endothelial cells, reticulum cells on adipocytes, except for TIMP-2 identification in stromal histiocytes. It is highly possible that these MMP and TIMP expressions in the BM hematopoietic cells and stromal histiocytes are significantly associated with suppression or induction of myelofibrosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938591     DOI: 10.1272/jnms.67.235

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  2 in total

Review 1.  New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis.

Authors:  Beate Heissig; Makiko Ohki-Koizumi; Yoshihiko Tashiro; Ismael Gritli; Kaori Sato-Kusubata; Koichi Hattori
Journal:  Int J Hematol       Date:  2012-02-07       Impact factor: 2.490

2.  Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study.

Authors:  Senem Maral; Muradiye Acar; Ozlem Sahin Balcik; Eyyup Uctepe; Omer Faruk Hatipoglu; Derya Akdeniz; Hatice Uludag Altun; Ali Kosar; Mehmet Gunduz; Esra Gunduz
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.